 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 305 | 回復(fù): 0 | ||
shmilymeng銀蟲(chóng) (初入文壇)
|
[求助]
Xadago - EPAR - Public assessment report + 臨床藥學(xué) + 2015/04/10
|
|
求專業(yè)人士幫忙翻譯臨床研究資料，多謝啊多謝�。�！ Adverse events with an occurrence rate of ≥5% have been underlined Although the incidence of bradycardia and arrhythmia as adverse events was slightly higher in the active treatment arms as compared to placebo, there was no clear signal of abnormalities from the ECGs, which were routinely monitored in the therapeutic clinical trials. There was no evidence of effect of safinamide on ECGs from the therapeutic clinical trials. In a randomized, double blind, placebo-controlled study in healthy subjects (trial 28559) the effects of Safinamide (100 and 350mg) on the QT/QTc interval have been investigated with Moxifloxacine (400mg) as a positive control. Safinamide was not associated with QTc prolongation in this trial. By contrast, in both the Moxifloxacin and supratherapeutic Safinamide group a mild PR shortening was observed (<4 msec for both groups). This level of effect, if caused by the drug, was considered of no clinical relevance. 2.8.2.6. Skin and subcutaneous tissue disorders For ESPD, the occurrence of skin and subcutaneous disorders decreased with increasing Safinamide dosage (50mg 11.7%; 150-200mg 4.5%). For LSPD patients, the occurrence rate was similar for 50 and 100mg Safinamide: 11.5%. These rates were higher compared to placebo (9.9%). In the open label studies 10% of patients experienced skin and subcutaneous tissue disorders. In this patient group, one patient experienced a melanoma. In the double-blind placebo-controlled trials none of the patients experienced melanoma. 2.8.2.7. Ocular adverse events In repeated-dose studies with Safinamide in rats retinal degeneration has been observed. In the chronic studies, these retinal alterations progressed to a stage where the outer nuclear layer disappeared and changes to the pigment epithelium. Loss of nuclei from the inner nuclear layer was also present. The lowest dose producing retinal atrophy was 15mg/kg/day. Thus far, these changes have not been noted in any human or non-human primate species in which ocular investigations have been performed. Once the potential of retinal degeneration had been observed, it was decided to introduce ocular investigations for the patients enrolled in the safinamide development program. Ocular examinations included: visual acuity, LogMAR assessment (chart to determine visual acuity), colour vision examination, funduscopy assessment, visual field assessment, global impression score of ocular function, occurrence of ocular TEAEs, ocular coherence tomography (OCT), and electroretinograms (ERG). The extent to which this was done differed between studies and research sites. Ocular images were assessed centrally by a neuro-ophthalmologist. As represented in the next Table 37, 30 retinal degeneration was observed in 2.2% of ESPD patients treated with 150-200mg per day in Study 017, in which there were no baseline ocular assessments. Retinal degeneration has not been observed in other ESPD patients. Retinal degeneration (LSPD patients) was observed in 2.1% of patients treated with 50mg safinamide per day and in 0.2% of patients who received 100mg safinamide per day. Also one placebo-treated patient experienced retinal degeneration (0.2% from the Placebo group). Cataract occurred in 3.5-5.6% of ESPD patients, compared to 6.3-14% of LSPD patients. Conjunctivitis occurred in less than 2% of both ESPD and LSPD patients. |
回復(fù)此樓» 猜你喜歡
279分求調(diào)劑 一志愿211
已經(jīng)有12人回復(fù)
-
297求調(diào)劑
已經(jīng)有9人回復(fù)
-
085700資源與環(huán)境308求調(diào)劑
已經(jīng)有13人回復(fù)
-
材料 336 求調(diào)劑
已經(jīng)有4人回復(fù)
-
華東師范大學(xué)-071000生物學(xué)-293分-求調(diào)劑
已經(jīng)有3人回復(fù)
-
280求調(diào)劑
已經(jīng)有8人回復(fù)
-
324分 085600材料化工求調(diào)劑
已經(jīng)有4人回復(fù)
-
一志愿華中科技大學(xué)，080502，354分求調(diào)劑
已經(jīng)有5人回復(fù)
-
一志愿武理材料305分求調(diào)劑
已經(jīng)有7人回復(fù)
-
271材料工程求調(diào)劑
已經(jīng)有8人回復(fù)
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 shmilymeng 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 材料 336 求調(diào)劑 +3 | An@. 2026-03-18 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 一志愿 西北大學(xué) ，070300化學(xué)學(xué)碩，總分287，雙非一本，求調(diào)劑。 +3 | 晨昏線與星海 2026-03-18 | 3/150 |
|
|
|
[考研] 324求調(diào)劑 +5 | lucky呀呀呀鴨 2026-03-20 | 5/250 |
|
|
|
[考研] 288求調(diào)劑 +16 | 于海海海海 2026-03-19 | 16/800 |
|
|
|
[考研] 290求調(diào)劑 +7 | ^O^乜 2026-03-19 | 7/350 |
|
|
|
[考研] 265求調(diào)劑 +12 | 梁梁校校 2026-03-19 | 13/650 |
|
|
|
[考研] 一志愿北京化工大學(xué)0703化學(xué)318分，有科研經(jīng)歷，求調(diào)劑 +4 | 一瓶苯甲酸 2026-03-14 | 4/200 |
|
|
|
[考研] 298-一志愿中國(guó)農(nóng)業(yè)大學(xué)-求調(diào)劑 +9 | 手機(jī)用戶 2026-03-17 | 9/450 |
|
|
|
[考研] 生物學(xué)調(diào)劑招人�。�！ +3 | 山海天嵐 2026-03-17 | 4/200 |
|
|
|
[考研] 288求調(diào)劑，一志愿華南理工大學(xué)071005 +5 | ioodiiij 2026-03-17 | 5/250 |
|
|
|
[考研] 一志愿福大288有機(jī)化學(xué)，求調(diào)劑 +3 | 小木蟲(chóng)200408204 2026-03-18 | 3/150 |
|
|
|
[考研] 328求調(diào)劑，英語(yǔ)六級(jí)551，有科研經(jīng)歷 +4 | 生物工程調(diào)劑 2026-03-16 | 12/600 |
|
|
|
[考研] 328求調(diào)劑，英語(yǔ)六級(jí)551，有科研經(jīng)歷 +3 | 生物工程調(diào)劑 2026-03-17 | 7/350 |
|
|
|
[考研] 085601專碩，總分342求調(diào)劑，地區(qū)不限 +5 | share_joy 2026-03-16 | 5/250 |
|
|
|
[考研] 收復(fù)試調(diào)劑生 +4 | 雨后秋荷 2026-03-18 | 4/200 |
|
|
|
[考博] 26博士申請(qǐng) +3 | 1042136743 2026-03-17 | 3/150 |
|
|
|
[考研] 277調(diào)劑 +5 | 自由煎餅果子 2026-03-16 | 6/300 |
|
|
|
[考研] 一志愿南京大學(xué)，080500材料科學(xué)與工程，調(diào)劑 +4 | Jy? 2026-03-16 | 4/200 |
|
|
|
[考研] 本科南京大學(xué)一志愿川大藥學(xué)327 +3 | 麥田耕者 2026-03-14 | 3/150 |
|
|
|
[考研] 297一志愿上交085600求調(diào)劑 +5 | 指尖八千里 2026-03-14 | 5/250 |
|